Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg, Twice-a-Day Dosage, Rx Only, 100 Cap...

FDA Recall #D-0097-2025 — Class II — November 1, 2024

Recall #D-0097-2025 Date: November 1, 2024 Classification: Class II Status: Ongoing

Product Description

Diltiazem Hydrochloride Extended-Release Capsules, USP 90mg, Twice-a-Day Dosage, Rx Only, 100 Capsules per bottle, Mfd for: Northstar Rx LLC, Memphis, TN, Mfd by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh India, NDC 16714-554-01.

Reason for Recall

cGMP Deviations: Presence of N-nitroso-Desmethyl-Diltiazem impurity above FDA recommended interim limit.

Recalling Firm

Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

4704 bottles

Distribution

Nationwide in the USA

Code Information

Lot #: 17222452, Exp Date 11/30/2024; 17230607, Exp Date 02/28/2025.

Status

Ongoing

Voluntary / Mandated

Voluntary: Firm initiated